Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
08
2021
accepted:
28
06
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
3
9
2022
Statut:
epublish
Résumé
The role of interferon gamma (IFN-γ) expression in long-term survival has not been studied in patients with urinary bladder cancer (UBC). IFN-γ expression was characterized among various UBC patient cohorts to assess if IFN-γ status is associated with overall survival (OS). A tumor-based IFN-γ gene signature was evaluated among adult UBC patients newly diagnosed between 2004 and 2017 from two hospital systems in New York. Patient cohorts included metastatic (stage IV or progressing to stage IV [MBC]), muscle-invasive (stages T2a to T4a [MIBC]), and non-muscle-invasive (carcinoma in situ or stages 0a, 0is, and I [NMIBC]) disease. Descriptive analyses were conducted comparing IFN-γ signature in the highest tertile to those in the lowest two tertiles. 234 patients with bladder cancer were evaluated (56 MBC, 38 MIBC, and 140 NMIBC). Median OS was only reached in the MIBC cohort for those with an IFN-γ signature in the lowest two tertiles (15.03 months [95% CI, 8.50-50.60]). Those with an IFN-γ signature in the highest tertile had a decreased risk of mortality in all cohorts indicating better survival, but this was statistically significant in only the MIBC cohort (adjusted HR = 0.09 [95% CI, 0.01-0.73]). IFN-γ signature status was associated with a decreased mortality risk in all cohorts, particularly MIBC, indicating that it may be a prognostic marker of survival in patients with UBC.
Sections du résumé
BACKGROUND
The role of interferon gamma (IFN-γ) expression in long-term survival has not been studied in patients with urinary bladder cancer (UBC). IFN-γ expression was characterized among various UBC patient cohorts to assess if IFN-γ status is associated with overall survival (OS).
METHODS
A tumor-based IFN-γ gene signature was evaluated among adult UBC patients newly diagnosed between 2004 and 2017 from two hospital systems in New York. Patient cohorts included metastatic (stage IV or progressing to stage IV [MBC]), muscle-invasive (stages T2a to T4a [MIBC]), and non-muscle-invasive (carcinoma in situ or stages 0a, 0is, and I [NMIBC]) disease. Descriptive analyses were conducted comparing IFN-γ signature in the highest tertile to those in the lowest two tertiles.
RESULTS
234 patients with bladder cancer were evaluated (56 MBC, 38 MIBC, and 140 NMIBC). Median OS was only reached in the MIBC cohort for those with an IFN-γ signature in the lowest two tertiles (15.03 months [95% CI, 8.50-50.60]). Those with an IFN-γ signature in the highest tertile had a decreased risk of mortality in all cohorts indicating better survival, but this was statistically significant in only the MIBC cohort (adjusted HR = 0.09 [95% CI, 0.01-0.73]).
CONCLUSION
IFN-γ signature status was associated with a decreased mortality risk in all cohorts, particularly MIBC, indicating that it may be a prognostic marker of survival in patients with UBC.
Identifiants
pubmed: 36040901
doi: 10.1371/journal.pone.0271339
pii: PONE-D-21-27722
pmc: PMC9426882
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271339Déclaration de conflit d'intérêts
Christina Gillezeau, Maaike van Gerwen and Emanuela Taioli declare no competing interests exist. Naimisha Movva and Jon Fryzek report grants from AstraZeneca. Karma Rabon-Stith, Norah Shire and Philip Zachary Brohawn report employment with AstraZeneca. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Urol. 2018 Mar;199(3):669-675
pubmed: 28882404
J Urol. 2007 Dec;178(6):2314-30
pubmed: 17993339
Eur Urol. 2008 Mar;53(3):581-9
pubmed: 17997024
Future Oncol. 2015;11(16):2299-306
pubmed: 26260808
Clin Colorectal Cancer. 2015 Dec;14(4):239-50
pubmed: 26524924
Cancer. 2010 Jun 1;116(11):2604-11
pubmed: 20310051
Cancer Immunol Res. 2015 Sep;3(9):1052-62
pubmed: 25943534
Cancer. 2010 Apr 1;116(7):1757-66
pubmed: 20143437
Cancer Discov. 2015 Jul;5(7):684-5
pubmed: 26034052
Clin Ter. ;168(1):e59-e63
pubmed: 28488840
World J Urol. 2009 Jun;27(3):289-93
pubmed: 19219610
Eur Urol. 2011 Jun;59(6):997-1008
pubmed: 21458150
Crit Rev Oncol Hematol. 2008 Aug;67(2):124-32
pubmed: 18375141
Cancer Immunol Immunother. 2007 Aug;56(8):1173-82
pubmed: 17186290
Oncoimmunology. 2018 Jul 23;7(9):e1476816
pubmed: 30228944
J Urol. 2002 Nov;168(5):1964-70
pubmed: 12394686
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
J Urol. 1976 Aug;116(2):180-3
pubmed: 820877
Cytokine Growth Factor Rev. 2016 Oct;31:73-81
pubmed: 27502919
J Clin Oncol. 2015 Feb 20;33(6):643-50
pubmed: 25559810
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446